[Cis-dichlorodiammineplatinum (II) in the treatment of a refractory non-Hodgkin's lymphoma with renal involvement].
A case of refractory non-Hodgkin's lymphoma with renal involvement that showed marked response to cis-dichlorodiammineplatinum (II) (CDDP) is reported. It is noteworthy that there was clear dissociation of responses between the renal lesion and extrarenal ones. CDDP is considered to be useful as part of a second line or salvage therapy for refractory non-Hodgkin's lymphoma.
D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D002945:Cisplatin / Q000627:therapeutic use*; D003131:Combined Modality Therapy; D004351:Drug Resistance; D006801:Humans; D007680:Kidney Neoplasms / Q000188:drug therapy*; D008223:Lymphoma / Q000188:drug therapy* / Q000473:pathology / Q000532:radiotherapy; D008297:Male; D008875:Middle Aged
D002945:Cisplatin